The Antitumor Agent CC-1065 Inhibits Helicase-Catalyzed Unwinding of Duplex DNA

Ira P. Maine, Daekyu Sun, Laurence H. Hurley, Thomas Kodadek

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

The antitumor drug CC-1065 is thought to exert its effects by covalent bonding to N3 of adenine in DNA and interfering with some aspect of DNA metabolism. Therefore, it is of interest to determine what effect this drug has on enzymes involved in various aspects of DNA metabolism. In this report, we examine the ability of two DNA helicases, the dda protein of phage T4 and helicase II of Escherichia coli, to unwind CC-1065-adducted, tailed, oligonucleotides. It is shown that the presence of the drug on DNA strongly inhibits unwinding catalyzed by the T4 and E. coli proteins. A significant difference between the results obtained with the two helicases is that DNAs containing drug on either the tailed or the completely duplex strands are poor substrates for helicase II but dda protein-mediated unwinding is inhibited only when the drug is on the tailed strand. The drug-modified, helicase-released, strands migrate abnormally through a native gel, suggesting that the drug traps an unusual secondary structure generated in the course of protein-mediated unwinding. A kinetic analysis of the drug-inhibited reactions reveals that the helicases are trapped by the DNA-drug complex. This is evidenced by a decrease in the rate of helicase exchange between drug-bound substrate and drug-free duplex. The implications of these results with respect to the mechanism of action of CC-1065 in vivo are discussed.

Original languageEnglish (US)
Pages (from-to)3968-3975
Number of pages8
JournalBiochemistry
Volume31
Issue number16
DOIs
StatePublished - Apr 1 1992
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry

Fingerprint

Dive into the research topics of 'The Antitumor Agent CC-1065 Inhibits Helicase-Catalyzed Unwinding of Duplex DNA'. Together they form a unique fingerprint.

Cite this